2011 in Review: A Year of Innovation, Record Net Cash and The Cultivation of Enterprise 3.0
As 2011 comes to a close, it offers us an opportunity to look back at the major milestones and key events of the year. While…
Posted by
Safeguard Insights
VIDEO: AdvantEdge Healthcare Solutions – Sustained Growth Over the Years
AdvantEdge Healthcare Solutions (AHS) has continued its steady growth rate, acquiring four companies since 2009, allowing the company to become one of the largest players…
Posted by
Week in Review: Why Startups Falter, Safeguard’s Strong Track Record, and Swap.com Defines an Industry
Contrary to popular belief, a startup’s success does not solely hinge on the idea, but the leadership and talent that drive the company forward. For…
Posted by
Week in Review: Convergence between Life Sciences and Technology and A Look at New Partner Company Medivo
The convergence between life sciences and technology cannot be ignored. That’s why at Safeguard Scientifics, we consolidated of our life sciences and technology deal teams.…
Posted by
Recap: Safeguard Scientifics Q3 2011 Financial Results
As Peter J. Boni highlighted this morning, despite volatile capital markets and a wobbly economy, Safeguard Scientifics continues to fire on all cylinders by realizing…
Posted by
Safeguard Scientifics to Announce Third Quarter 2011 Financial Results on October 26
Safeguard Scientifics will release its financial results for the third quarter ended September 30, 2011 prior to market open on Wednesday, October 26. At 9…
Posted by
Week in Review: Boni’s Big Decision, Putney Joins the Team, and Tengion Blooms with Flora
Apple dominated the headlines this week with the release of its new phone, the iPhone 4S. The show-stopper was Siri, a revolutionary voice activated assistant…
Posted by
Drivers of our Economic Engine: Safeguard Scientifics’ Inc. 500|5000 Partner Companies
It’s no secret that fast-growing, private start-up companies are a catalyst for new job creation. According to Inc., more than 370,592 jobs have been created…
Posted by
NuPathe: FDA CRL Doesn’t Reject NDA or Impact Potential Long-Term Value, Only Delays Launch
The line between long-term value creation and short-term speculative trading was never as stark as it was this week on Tuesday, August 30, after life…
Posted by
